(Circulation. 2005;111:e394-e434.)
© 2005 American Heart Association, Inc.
AHA Scientific Statement |


Correspondence to Kathryn A. Taubert, PhD, FAHA, American Heart Association, 7272 Greenville Ave, Dallas, TX 75231. E-mail Ktaubert{at}heart.org
Background— Despite advances in medical, surgical, and critical care interventions, infective endocarditis remains a disease that is associated with considerable morbidity and mortality. The continuing evolution of antimicrobial resistance among common pathogens that cause infective endocarditis creates additional therapeutic issues for physicians to manage in this potentially life-threatening illness.
Methods and Results— This work represents the third iteration of an infective endocarditis "treatment" document developed by the American Heart Association under the auspices of the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease of the Young. It updates recommendations for diagnosis, treatment, and management of complications of infective endocarditis. A multidisciplinary committee of experts drafted this document to assist physicians in the evolving care of patients with infective endocarditis in the new millennium. This extensive document is accompanied by an executive summary that covers the key points of the diagnosis, antimicrobial therapy, and management of infective endocarditis. For the first time, an evidence-based scoring system that is used by the American College of Cardiology and the American Heart Association was applied to treatment recommendations. Tables also have been included that provide input on the use of echocardiography during diagnosis and treatment of infective endocarditis, evaluation and treatment of culture-negative endocarditis, and short-term and long-term management of patients during and after completion of antimicrobial treatment. To assist physicians who care for children, pediatric dosing was added to each treatment regimen.
Conclusions— The recommendations outlined in this update should assist physicians in all aspects of patient care in the diagnosis, medical and surgical treatment, and follow-up of infective endocarditis, as well as management of associated complications. Clinical variability and complexity in infective endocarditis, however, dictate that these guidelines be used to support and not supplant physician-directed decisions in individual patient management.
Key Words: AHA Scientific Statements endocardium drugs echocardiography infection
This article has been cited by other articles:
![]() |
D. E. Troise, G. F. Guarnieri, N. Laforgia, M. R. Tagliente, T. Pirolo, P. Arciprete, and L. de Luca Tupputi Schinosa Multidisciplinary approach in a case of successful surgical treatment of a voluminous intracardiac fungal mass in an infant Eur J Echocardiogr, May 1, 2008; 9(3): 317 - 318. [Full Text] [PDF] |
||||
![]() |
F. Rouzet, M. D. Hernandez, F. Hervatin, L. Sarda-Mantel, A. Lefort, X. Duval, L. Louedec, B. Fantin, D. Le Guludec, and J.-B. Michel Technetium 99m-Labeled Annexin V Scintigraphy of Platelet Activation in Vegetations of Experimental Endocarditis Circulation, February 12, 2008; 117(6): 781 - 789. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. W. M. Verhagen, J. Hermanides, J. C. Korevaar, P. M. M. Bossuyt, R. B. A. van den Brink, P. Speelman, and J. T. M. van der Meer Prognostic Value of Serial C-Reactive Protein Measurements in Left-Sided Native Valve Endocarditis Arch Intern Med, February 11, 2008; 168(3): 302 - 307. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. C. Millar, B. D. Prendergast, and J. E. Moore Community-associated MRSA (CA-MRSA): an emerging pathogen in infective endocarditis J. Antimicrob. Chemother., January 1, 2008; 61(1): 1 - 7. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Wilson, K. A. Taubert, M. Gewitz, P. B. Lockhart, L. M. Baddour, M. Levison, A. Bolger, C. H. Cabell, M. Takahashi, R. S. Baltimore, et al. Prevention of infective endocarditis: Guidelines from the American Heart Association: A guideline from the American Heart Association Rheumatic Fever, Endocarditis and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group J Am Dent Assoc, January 1, 2008; 139(suppl_1): 3S - 24S. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-F. Avierinos, F. Thuny, V. Chalvignac, R. Giorgi, L. Tafanelli, J.-P. Casalta, D. Raoult, T. Mesana, F. Collart, D. Metras, et al. Surgical Treatment of Active Aortic Endocarditis: Homografts Are Not the Cornerstone of Outcome Ann. Thorac. Surg., December 1, 2007; 84(6): 1935 - 1942. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. R. Vikram, A. K. Bacani, P. A. DeValeria, S. A. Cunningham, and F. R. Cockerill III Bivalvular Bartonella henselae Prosthetic Valve Endocarditis J. Clin. Microbiol., December 1, 2007; 45(12): 4081 - 4084. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Wilson, K. A. Taubert, M. Gewitz, P. B. Lockhart, L. M. Baddour, M. Levison, A. Bolger, C. H. Cabell, M. Takahashi, R. S. Baltimore, et al. Prevention of Infective Endocarditis: Guidelines From the American Heart Association: A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group Circulation, October 9, 2007; 116(15): 1736 - 1754. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Nucifora, L. P. Badano, P. Viale, P. Gianfagna, G. Allocca, D. Montanaro, U. Livi, and P. M. Fioretti Infective endocarditis in chronic haemodialysis patients: an increasing clinical challenge Eur. Heart J., October 1, 2007; 28(19): 2307 - 2312. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. A Mergenhagen and M. T Pasko Daptomycin Use After Vancomycin-Induced Neutropenia in a Patient with Left-Sided Endocarditis Ann. Pharmacother., September 1, 2007; 41(9): 1531 - 1535. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Skiadas, A. Pefanis, A. Papalois, A. Kyroudi, H. Triantafyllidi, T. Tsaganos, and H. Giamarellou Dexamethasone as Adjuvant Therapy to Moxifloxacin Attenuates Valve Destruction in Experimental Aortic Valve Endocarditis Due to Staphylococcus aureus Antimicrob. Agents Chemother., August 1, 2007; 51(8): 2848 - 2854. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Falagas, K. P. Giannopoulou, F. Ntziora, and K. Z. Vardakas Daptomycin for endocarditis and/or bacteraemia: a systematic review of the experimental and clinical evidence J. Antimicrob. Chemother., July 1, 2007; 60(1): 7 - 19. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Musci, H. Siniawski, M. Pasic, O. Grauhan, Y. Weng, R. Meyer, C. A. Yankah, and R. Hetzer Surgical treatment of right-sided active infective endocarditis with or without involvement of the left heart: 20-year single center experience Eur. J. Cardiothorac. Surg., July 1, 2007; 32(1): 118 - 125. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Miro, C. Garcia-de-la-Maria, Y. Armero, E. de-Lazzari, D. Soy, A. Moreno, A. del Rio, M. Almela, C. A. Mestres, J. M. Gatell, et al. Efficacy of Telavancin in the Treatment of Experimental Endocarditis Due to Glycopeptide-Intermediate Staphylococcus aureus Antimicrob. Agents Chemother., July 1, 2007; 51(7): 2373 - 2377. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Greig, C. E. O'Sullivan, O. Adam, H. H. Klein, and H.-J. Schafers Intraaortic Vegetations and Infective Endocarditis N. Engl. J. Med., June 7, 2007; 356(23): 2430 - 2431. [Full Text] [PDF] |
||||
![]() |
W. Wilson, K. A. Taubert, M. Gewitz, P. B. Lockhart, L. M. Baddour, M. Levison, A. Bolger, C. H. Cabell, M. Takahashi, R. S. Baltimore, et al. Prevention of infective endocarditis: Guidelines from the American Heart Association: A guideline from the American Heart Association Rheumatic Fever, Endocarditis and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group J Am Dent Assoc, June 1, 2007; 138(6): 739 - 760. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Kamalakannan, R. M. Pai, L. B. Johnson, J. M. Gardin, and L. D. Saravolatz Epidemiology and Clinical Outcomes of Infective Endocarditis in Hemodialysis Patients Ann. Thorac. Surg., June 1, 2007; 83(6): 2081 - 2086. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Skubas, R. L. Slepian, L. Y. Lee, and A. J. Tortolani Tricuspid Regurgitation Caused by Eustachian Valve Endocarditis Anesth. Analg., December 1, 2006; 103(6): 1410 - 1411. [Full Text] [PDF] |
||||
![]() |
B. Hoen Epidemiology and antibiotic treatment of infective endocarditis: an update. Heart, November 1, 2006; 92(11): 1694 - 1700. [Full Text] [PDF] |
||||
![]() |
R. P Beynon, V K Bahl, and B. D Prendergast Infective endocarditis BMJ, August 12, 2006; 333(7563): 334 - 339. [Full Text] [PDF] |
||||
![]() |
R. O. Bonow, B. A. Carabello, K. Chatterjee, A. C. de Leon Jr, D. P. Faxon, M. D. Freed, W. H. Gaasch, B. W. Lytle, R. A. Nishimura, P. T. O'Gara, et al. ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) Developed in Collaboration With the Society of Cardiovascular Anesthesiologists Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons J. Am. Coll. Cardiol., August 1, 2006; 48(3): e1 - e148. [Full Text] [PDF] |
||||
![]() |
R. O. Bonow, B. A. Carabello, K. Chatterjee, A. C. de Leon Jr, D. P. Faxon, M. D. Freed, W. H. Gaasch, B. W. Lytle, R. A. Nishimura, P. T. O'Gara, et al. ACC/AHA 2006 Practice Guidelines for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) Developed in Collaboration With the Society of Cardiovascular Anesthesiologists Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons J. Am. Coll. Cardiol., August 1, 2006; 48(3): 598 - 675. [Full Text] [PDF] |
||||
![]() |
M. E. Falagas, K. G. Manta, F. Ntziora, and K. Z. Vardakas Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence J. Antimicrob. Chemother., August 1, 2006; 58(2): 273 - 280. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. Baddour, J. M. Steckelberg, and W. R. Wilson Comment on: The role of aminoglycosides in combination with a {beta}-lactam for the treatment of bacterial endocarditis: a meta-analysis of comparative trials J. Antimicrob. Chemother., June 1, 2006; 57(6): 1255 - 1255. [Full Text] [PDF] |
||||
![]() |
M. E. Falagas, D. K. Matthaiou, and I. A. Bliziotis Aminoglycosides in combination with a {beta}-lactam for the treatment of bacterial endocarditis: authors' response J. Antimicrob. Chemother., June 1, 2006; 57(6): 1255 - 1256. [Full Text] [PDF] |
||||
![]() |
M. E. Falagas, D. K. Matthaiou, and I. A. Bliziotis The role of aminoglycosides in combination with a {beta}-lactam for the treatment of bacterial endocarditis: a meta-analysis of comparative trials J. Antimicrob. Chemother., April 1, 2006; 57(4): 639 - 647. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Gordon and F. D. Lowy Bacterial infections in drug users. N. Engl. J. Med., November 3, 2005; 353(18): 1945 - 1954. [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2005 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |